Context sidebar

Public Summary SwissPAR

Following the entry into force of the revised therapeutic products legislation on 1 January 2019, Swissmedic is publishing abridged versions of the Swiss Public Assessment Report (SwissPAR for short), which are available to the general public. This affects applications for authorisation submitted on or after 1.1.2019.

In addition to the full SwissPAR, Swissmedic is publishing an abridged version of the SwissPAR known as the ‘Public Summary SwissPAR’. The Public Summary SwissPAR is intended to make Swissmedic's authorisation decisions comprehensible and transparent to the wider public, and to give them access to relevant information on medicinal products.

The Public Summary SwissPAR is based on the content of the published SwissPAR and the officially approved product information texts.

News

Public Summary SwissPAR – Elucirem®

First authorisation

Public Summary SwissPAR – Jaypirca®

First authorisation

Public Summary SwissPAR – Evusheld®

Extension of therapeutic indication (01)

Public Summary SwissPAR – Nuceiva®

First authorisation

Public Summary SwissPAR – Ryeqo®

First authorisation

Suche nach Präparatenamen 

    Suchergebnisse

    0 Ergebnisse gefunden

    Dokumente

    Dokumente

    Sorted...

    Sorted by name of the medicinal product

    A - C

    Public Summary SwissPAR – Adtralza®

    First authorisation

    Public Summary SwissPAR – Aklief®

    First authorisation

    Public Summary SwissPAR – Alhemo®

    First authorisation

    Public Summary SwissPAR – Alunbrig®

    First authorisation

    Public Summary SwissPAR – Aspaveli®

    First authorisation

    Public Summary SwissPAR – BCG Apogepha®

    First authorisation

    Public Summary SwissPAR – Beovu®

    First authorisation

    Public Summary SwissPAR – Beovu®

    Extension of therapeutic indication (01)

    Public Summary SwissPAR – Besremi®

    First authorisation

    Public Summary SwissPAR – Bimzelx®

    First authorisation

    Public Summary SwissPAR – Blenrep®

    First authorisation

    Public Summary SwissPAR – Brukinsa®

    First authorisation

    Public Summary SwissPAR – Brukinsa®

    Extension of therapeutic indication (01)

    Public Summary SwissPAR – Cablivi®

    First authorisation

    Public Summary SwissPAR – Cablivi®

    Indication extension (01)

    Public Summary SwissPAR – Calquence®

    First authorisation

    Public Summary SwissPAR – Camzyos®

    First authorisation

    Public Summary SwissPAR – Carbaglu®

    First authorisation

    Public Summary SwissPAR – Cibinqo®

    First authorisation

    Public Summary SwissPAR – Clofara®

    First authorisation

    Public Summary SwissPAR – Colibiogen Oral®

    First authorisation

    Public Summary SwissPAR – Columvi®

    First authorisation

    Public Summary SwissPAR – Comirnaty®

    First authorisation

    Public Summary SwissPAR – Condrosulf Plus®

    First authorisation

    Public Summary SwissPAR – COVID-19 Vaccine Janssen®

    First authorisation

    D - F

    Public Summary SwissPAR – Defitelio®

    First authorisation

    Public Summary SwissPAR – Doptelet®

    First authorisation

    Public Summary SwissPAR – Drovelis®

    First authorisation

    Public Summary SwissPAR – Efluelda®

    First authorisation

    Public Summary SwissPAR – Elfabrio®

    First authorisation

    Public Summary SwissPAR – Elrexfio®

    First authorisation

    Public Summary SwissPAR – Elucirem®

    First authorisation

    Public Summary SwissPAR – ELZONRIS®

    First authorisation

    Public Summary SwissPAR – Enhertu®

    First authorisation

    Public Summary SwissPAR – Enhertu®

    Extension of therapeutic indication (01)

    Public Summary SwissPAR – Enspryng®

    First authorisation

    Public Summary SwissPAR – Epidyolex®

    First authorisation

    Public Summary SwissPAR – Epidyolex®

    Extension of therapeutic indication (01)

    Public Summary SwissPAR – Evrysdi®

    First authorisation

    Public Summary SwissPAR – Evrysdi®

    Extension of therapeutic indication (01)

    Public Summary SwissPAR – Evusheld®

    First authorisation

    Public Summary SwissPAR – Evusheld®

    Extension of therapeutic indication (01)

    Public Summary SwissPAR – Exkivity®

    First authorisation

    Public Summary SwissPAR – Fluenz Tetra®

    First authorisation

    G - K

    Public Summary SwissPAR – Gavreto®

    First authorisation

    Public Summary SwissPAR – Heparin Sintetica®

    First authorisation

    First authorisation

    Public Summary SwissPAR – Imjudo®

    First authorisation

    Public Summary SwissPAR – Inrebic®

    First authorisation

    Public Summary SwissPAR – Jaypirca®

    First authorisation

    Public Summary SwissPAR – Jemperli®

    First authorisation

    Public Summary SwissPAR – Kapruvia®

    First authorisation

    Public Summary SwissPAR – Kerendia®

    First authorisation

    Public Summary SwissPAR – Klisyri®

    First authorisation

    Public Summary SwissPAR – Koselugo®

    First authorisation

    L - N

    Public Summary SwissPAR – Lamzede®

    First authorisation

    Public Summary SwissPAR – Letybo®

    First authorisation

    Public Summary SwissPAR – Locametz®

    First authorisation

    Public Summary SwissPAR – Lokelma®

    First authorisation

    Public Summary SwissPAR – Lumykras®

    First authorisation

    Public Summary SwissPAR – Lunsumio®

    First authorisation

    Public Summary SwissPAR – Lupkynis®

    First authorisation

    Public Summary SwissPAR – Luxturna®

    First authorisation

    Public Summary SwissPAR – Lyfnua®

    First authorisation

    Public Summary SwissPAR – MenQuadfi®

    First authorisation

    Public Summary SwissPAR – Mictonorm®

    First authorisation

    Public Summary SwissPAR – milgamma®

    First authorisation

    Public Summary SwissPAR – Minjuvi®

    First authorisation

    Public Summary SwissPAR – Mounjaro®

    First authorisation

    Public Summary SwissPAR – NexoBrid®

    First authorisation

    Public Summary SwissPAR – Nexviadyme®

    First authorisation

    Public Summary SwissPAR – Ngenla®

    First authorisation

    Public Summary SwissPAR – Nicardipin Labatec®

    First authorisation

    Public Summary SwissPAR – Nilemdo®

    First authorisation

    Public Summary SwissPAR – Nityr®

    First authorisation

    Public Summary SwissPAR – Nubeqa®

    First authorisation

    Public Summary SwissPAR – Nubeqa®

    Extension of therapeutic indication (01)

    Public Summary SwissPAR – Nuceiva®

    First authorisation

    Public Summary SwissPAR – Nuvaxovid®

    First authorisation

    Public Summary SwissPAR – Nuvaxovid®

    Extension of therapeutic indication (01)

    O - R

    Public Summary SwissPAR – Ondexxya®

    First authorisation

    Public Summary SwissPAR – Onpattro®

    First authorisation

    Public Summary SwissPAR – Ontozry®

    First authorisation

    Public Summary SwissPAR – Opdualag®

    First authorisation

    Public Summary SwissPAR – Orladeyo®

    First authorisation

    Public Summary SwissPAR – Palforzia®

    First authorisation

    Public Summary SwissPAR – Paxlovid®

    First authorisation

    Public Summary SwissPAR – Pemazyre®

    First authorisation

    Public Summary SwissPAR – Pheburane®

    First authorisation

    Public Summary SwissPAR – Piqray®

    First authorisation

    Public Summary SwissPAR – Polivy®

    First authorisation

    Public Summary SwissPAR – Ponvory®

    First authorisation

    Public Summary SwissPAR – Poteligeo®

    First authorisation

    Public Summary SwissPAR – Qinlock®

    First authorisation

    Public Summary SwissPAR – QUVIVIQ®

    First authorisation

    Public Summary SwissPAR – Rapibloc®

    First authorisation

    Public Summary SwissPAR –Regkirona®

    First authorisation

    Public Summary SwissPAR – Retsevmo®

    First authorisation

    Public Summary SwissPAR – Rinvoq®

    First authorisation

    Public Summary SwissPAR – Rinvoq®

    Indication extension (01)

    Public Summary SwissPAR – Rinvoq®

    Indication extension (02)

    Public Summary SwissPAR – Rinvoq®

    Indication extension (03)

    Public Summary SwissPAR – Roclanda®

    First authorisation

    Public Summary SwissPAR – Ronapreve®

    First authorisation

    Public Summary SwissPAR – Rozlytrek®

    First authorisation

    Public Summary SwissPAR – Rubraca®

    First authorisation

    Public Summary SwissPAR – Rukobia®

    First authorisation

    Public Summary SwissPAR – Rybelsus®

    First authorisation

    Public Summary SwissPAR – Rybrevant®

    First authorisation

    Public Summary SwissPAR – Ryeqo®

    First authorisation

    S - U

    Public Summary SwissPAR – Saphnelo®

    First authorisation

    Public Summary SwissPAR – Sarclisa®

    First authorisation

    Public Summary SwissPAR – Scemblix®

    First authorisation

    Public Summary SwissPAR – Shingrix®

    First authorisation

    Public Summary SwissPAR – Softigyn®

    First authorisation

    Public Summary SwissPAR – Solmucol Bronchoprotect®

    First authorisation

    Public Summary SwissPAR – Spaverin®

    First authorisation

    Public Summary SwissPAR – Spevigo®

    First authorisation

    Public Summary SwissPAR – Spikevax®

    First authorisation

    Public Summary SwissPAR – Spravato®

    First authorisation

    Public Summary SwissPAR – Spravato®

    Extension of therapeutic indication (01)

    Public Summary SwissPAR – Sunlenca®

    First authorisation

    Public Summary SwissPAR – Sunosi®

    First authorisation

    Public Summary SwissPAR – Supemtek®

    First authorisation

    Public Summary SwissPAR – Tabrecta®

    First authorisation

    Public Summary SwissPAR – Talvey®

    First authorisation

    Public Summary SwissPAR – Tavneos®

    First authorisation

    Public Summary SwissPAR – Tecvayli®

    First authorisation

    Public Summary SwissPAR – Tenkasi®

    First authorisation

    Public Summary SwissPAR – Tenkasi®

    Extension of therapeutic indication (01)

    Public Summary SwissPAR – Tepmetko®

    First authorisation

    Public Summary SwissPAR – Tezspire®

    First authorisation

    Public Summary SwissPAR – Trecondi®

    First authorisation

    Public Summary SwissPAR – Trikafta®

    First authorisation

    Public Summary SwissPAR – Trikafta®

    Extension of therapeutic indication (01)

    Public Summary SwissPAR – Trikafta®

    Extension of therapeutic indication (02)

    Public Summary SwissPAR – Triogen®

    First authorisation

    Public Summary SwissPAR – Trodelvy®

    First authorisation

    Public Summary SwissPAR – Tukysa®

    First authorisation

    Public Summary SwissPAR – Ultomiris®

    First authorisation

    Public Summary SwissPAR – Ultomiris®

    Extension of therapeutic indication (01)

    Public Summary SwissPAR – Ultomiris®

    Extension of therapeutic indication (02)

    Public Summary SwissPAR – Ultomiris®

    Extension of therapeutic indication (03)

    V - Z

    Public Summary SwissPAR – Vaborem®

    First authorisation

    Public Summary SwissPAR – Vabysmo®

    First authorisation

    Public Summary SwissPAR – Vafseo®

    First authorisation

    Public Summary SwissPAR – VAZKEPA®

    First authorisation

    Public Summary SwissPAR – Veklury®

    First authorisation

    Public Summary SwissPAR – Veklury®

    Extension of therapeutic indication (01)

    Public Summary SwissPAR – Veklury®

    Extension of therapeutic indication (02)

    Public Summary SwissPAR – Verdye®

    First authorisation

    Public Summary SwissPAR – Verquvo®

    First authorisation

    Public Summary SwissPAR – Vocabria®

    First authorisation

    Public Summary SwissPAR – Vydura®

    First authorisation

    Public Summary SwissPAR – Vyepti®

    First authorisation

    Public Summary SwissPAR – Vyndaqel®

    First authorisation

    Public Summary SwissPAR – Xevudy®

    First authorisation

    Public Summary SwissPAR – Xofluza®

    First authorisation

    Public Summary SwissPAR – Xofluza®

    Extension of therapeutic indication (01)

    Public Summary SwissPAR – Xospata®

    First authorisation

    Public Summary SwissPAR – Zeposia®

    First authorisation

    Public Summary SwissPAR – Zeposia®

    Extension of therapeutic indication (01)

    Public Summary SwissPAR – Zepzelca®

    First authorisation

    Top of page